A chemically synthesized copy (S-CB7) of a fragment (35 amino acid residues) of type 24 
Recently my co-workers and I established that short synthetic peptide fragments of streptococcal M protein containing as few as 13 amino acid residues evoked protective immunity against the related streptococci if the peptides were covalently linked to polylysine or tetanus toxoid and emulsified in complete Freund adjuvant (1, 2, 5, 10) . The need for Freund adjuvant restricts the use of such vaccines to animal studies, because the toxicity of the adjuvant is too great for human use. We have examined more closely the immune response of rabbits to a synthetic peptide (S-CB7) of type 24 M protein linked with carbodiimide to polylysine and injected subcutaneously in phosphate-buffered saline (PBS; 0.15 M NaCl plus 0.02 M phosphate, pH 7.4) alone or with an initial dose of a synthetic adjuvant, a butyl derivative of muramyl dipeptide (N-acetylmuramyl-L-alanyl-D-glutamylot-n-butyl ester) currently undergoing clinical trials (6) . The brisk immune response to a single 25-nmol dose of S-CB7 linked to polylysine and emulsified in complete Freund adjuvant was reported previously (2) . Without conjugation, the protective immune responses to the synthetic peptide were weak even when the peptide was emulsified in complete Freund adjuvant before injection (2) . I now report data to show that when conjugated to polylysine, S-CB7 is highly immunogenic in rabbits without adjuvant.
S-CB7, the chemically synthesized cyanogen bromidederived fragment 7 of a pepsin-extracted type 24 M protein (pep M24), was prepared as previously described (1, 2, 5, 10) using an automated peptide synthesizer (Beckman Instruments, Inc., Fullerton, Calif.). The synthetic peptide was purified by molecular-sieve chromatography on a column of Sephadex G-50 and further purified by high-pressure liquid chromatography (1, 5) . The primary structure of S-CB7 was confirmed by quantitative amino acid analysis and by Edman degradation to the penultimate amino acid residue (5) . The sequence of S-CB7 has been reported (2) as follows: 5 10 Asn-Phe-Ser-Thr-Ala-Asp-Ser-Ala-Lys-Ile-Lys-Thr-Leu- Glu-Ala-Glu-Lys-Ala-Ala-Leu-Ala-Ala-Arg-Lys-Ala-Asp-
35
Leu-Glu-Lys-Ala-Leu-Glu-Gly-Ala-Met
The purified peptide was covalently linked to polylysine with carbodiimide (2). The conjugate (25 nmol of peptide) was dissolved in PBS and injected subcutaneously behind the neck of rabbits with or without 100 ,ug of murabutide. Rabbit sera were collected at 2-week intervals and tested by enzyme-linked immunosorbent assays (ELISA) and opsonophagocytosis tests as previously described (1 a The test mixtures each consisted of 0.4 ml of fresh, heparinized (10 U/ml) human blood, 0.05 ml of streptococcal inoculum suspended in PBS, and 0.05 ml of preimmune or immune rabbit serum (4) . After incubation at 37°C by rotation end-over-end at 8 rpm for 3 h, blood agar pour plates were prepared from each mixture to determine growth of CFU (4 were in the same range as those in the rabbits receiving a dose of the synthetic adjuvant, murabutide, in conjunction with the initial immunizing dose of S-CB7. I do not mean to imply that murabutide is not effective as an adjuvant, be- cause our studies do not allow such a speculation. The purpose of this paper rather is to show that even in the absence of adjuvant one can obtain a protective immune response to a synthetic peptide copy of M protein.
In a previous study (11), we demonstrated that glutaraldehyde-polymerized S-CB7, but not monomeric S-CB7, was capable of evoking secondary immune responses in animals given an initial priming dose of pep M24 in PBS. Pep M24, however, is a large polypeptide fragment of Mr 33,500; the intact M24 protein appears to have a molecular weight of ca. 76,000 (unpublished data), while that of S-CB7 is ca. 4,000 (4) . The conjugate formed between S-CB7 and polylysine would have a minimum calculated molecular weight of 39,000. The multivalency of the S-CB7 polylysine conjugate in combination with the positive charge conferred by the polylysine probably accounts for its greater immunogenicity as compared with the monomeric form of S-CB7 (2).
The findings reported here may have bearing on the development of protective bacterial vaccines for human use. The ability to evoke protective antistreptococcal antibodies in the absence of adjuvants would circumvent the potential problems arising from the use of these agents. The use of selected peptide fragments, rather than the parent molecule or even the large polypeptide fragment extracted by limited digestion with pepsin, allows disposal of a large part of the M protein molecule which may contain potentially harmful antigenic determinants giving rise to immunological crossreactions with host tissues (7) (8) (9) (12) (13) (14) . The selection of small peptide regions that contain protective epitopes should shed light not only on the composition of the protective antigenic determinants of the M protein, but also on the mechanisms of acute rheumatic fever and rheumatic heart disease, the pathogenesis of which up to now has remained an enigma. I 
